#oral medication

Structure Therapeutics ने अपने मौखिक GLP-1 रिसेप्टर एगोनिस्ट के लिए प्रोत्साहजनक चरण 2 परिणाम रिपोर्ट किए हैं, इंजेक्टेबल वजन-घटाने और मधुमेह दवाओं के लिए एक गोली-रूप विकल्प को आगे बढ़ाया है।

After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.